Quantification of β-cell insulin secretory function using a graded glucose infusion with C-peptide deconvolution in dysmetabolic, and diabetic cynomolgus monkeys

Diabetology & Metabolic Syndrome

Yi-Xin Jim Wang¹  Francine M Gregoire¹  Yaxiong Michael Chen³  Bingdi Wang¹  Fenglai Du¹  Yupeng Fang¹  Da Shi³  Barbara C Hansen²  Xiaoli Wang¹ 

[1] International Institute of Biomedical Research (IIBR), a Crown Bioscience Company at David H. Murdock Research Institute (DHMRI), Kannapolis, NC, USA;Departments of Internal Medicine and Pediatrics, and Obesity, Diabetes and Aging Research Center, University of South Florida, Tampa, FL, USA;Cardiovascular and Metabolic Diseases Research, Crown Bioscience Inc., 6 Beijing West Road, Science & Technology Park, Taicang Economic Development Area, Taicang, Jiangsu Province 215400, P.R. China

关键词: Nonhuman primate;    Hepatic insulin extraction;    Diabetes;    β-cell failure;    Insulin resistance;    GGI;    Graded glucose infusion;    Deconvolution;    C-peptide;    Insulin secretion rate;   

Others  :  821687
DOI  :  10.1186/1758-5996-5-40

 received in 2013-04-11, accepted in 2013-07-16,  发布年份 2013

【 摘 要 】

Background

Quantitation of β-cell function is critical in better understanding of the dynamic interactions of insulin secretion, clearance and action at different phases in the progression of diabetes. The present study aimed to quantify β-cell secretory function independently of insulin sensitivity in the context of differential metabolic clearance rates of insulin (MCRI) in nonhuman primates (NHPs).

Methods

Insulin secretion rate (ISR) was derived from deconvolution of serial C-peptide concentrations measured during a 5 stage graded glucose infusion (GGI) in 12 nondiabetic (N), 8 prediabetic or dysmetabolic (DYS) and 4 overtly diabetic (DM) cynomolgus monkeys. The characterization of the monkeys was based on the fasting glucose and insulin concentrations, glucose clearance rate measured by intravenous glucose tolerance test, and insulin resistance indices measured in separate experiments. The molar ratio of C-peptide/insulin (C/I) was used as a surrogate index of hepatic MCRI.

Results

Compared to the N monkeys, the DYS with normal glycemia and hyperinsulinemia had significantly higher basal and GGI-induced elevation of insulin and C-peptide concentrations and lower C/I, however, each unit of glucose-stimulated ISR increment was not significantly different from that in the N monkeys. In contrast, the DM monkeys with β-cell failure and hyperglycemia had a depressed GGI-stimulated ISR response and elevated C/I.

Conclusions

The present data demonstrated that in addition to β-cell hypersecretion of insulin, reduced hepatic MCRI may also contribute to the development of hyperinsulinemia in the DYS monkeys. On the other hand, hyperinsulinemia may cause the saturation of hepatic insulin extraction capacity, which in turn reduced MCRI in the DYS monkeys. The differential contribution of ISR and MCRI in causing hyperinsulinemia provides a new insight into the trajectory of β-cell dysfunction in the development of diabetes. The present study was the first to use the GGI and C-peptide deconvolution method to quantify the β-cell function in NHPs.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]De Koning EJ, Bodkin NL, Hansen BC, Clark A: Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia 1993, 36:378-384.
• [2]Guardado-Mendoza R, Davalli AM, Chavez AO, Hubbard GB, Dick EJ, Majluf-Cruz A, Tene-Perez CE, Goldschmidt L, Hart J, Perego C, et al.: Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci USA 2009, 106:13992-13997.
• [3]Hansen BC, Vinik A, Jen KL, Schielke GP: Fluctuations in basal levels and effects of altered nutrition on plasma somatostatin. Am J Physiol 1982, 243:R289-R295.
• [4]Ferrannini E, Cobelli C: The kinetics of insulin in man. II. Role of the liver. Diabetes Metab Rev 1987, 3:365-397.
• [5]Ferrannini E, Cobelli C: The kinetics of insulin in man. I. General aspects. Diabetes Metab Rev 1987, 3:335-363.
• [6]Hansen BC, Striffler JS, Bodkin NL: Decreased hepatic insulin extraction precedes overt noninsulin dependent (Type II) diabetes in obese monkeys. Obes Res 1993, 1:252-260.
• [7]Hovorka R, Jones RH: How to measure insulin secretion. Diabetes Metab Rev 1994, 10:91-117.
• [8]Hovorka R, Soons PA, Young MA: ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 1996, 50:253-264.
• [9]Van Cauter E, Mestrez F, Sturis J, Polonsky KS: Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992, 41:368-377.
• [10]Letiexhe MR, Scheen AJ, Gerard PL, Desaive C, Lefebvre PJ: Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects. Int J Obes Relat Metab Disord 1994, 18:295-300.
• [11]Letiexhe MR, Scheen AJ, Gerard PL, Desaive C, Lefebvre PJ: Postgastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab 1995, 80:364-369.
• [12]Jimenez J, Zuniga-Guajardo S, Zinman B, Angel A: Effects of weight loss in massive obesity on insulin and C-peptide dynamics: sequential changes in insulin production, clearance, and sensitivity. J Clin Endocrinol Metab 1987, 64:661-668.
• [13]Zuniga-Guajardo S, Jimenez J, Angel A, Zinman B: Effects of massive obesity on insulin sensitivity and insulin clearance and the metabolic response to insulin as assessed by the euglycemic clamp technique. Metabolism 1986, 35:278-282.
• [14]Ehrmann DA, Breda E, Cavaghan MK, Bajramovic S, Imperial J, Toffolo G, Cobelli C, Polonsky KS: Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia 2002, 45:509-517.
• [15]Kim SH, Abbasi F, Chu JW, McLaughlin TL, Lamendola C, Polonsky KS, Reaven GM: Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes 2005, 54:2447-2452.
• [16]Toffolo G, Breda E, Cavaghan MK, Ehrmann DA, Polonsky KS, Cobelli C: Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab 2001, 280:E2-E10.
• [17]Hansen BC: Investigation and treatment of type 2 diabetes in nonhuman primates. Methods Mol Biol 2012, 933:177-185.
• [18]Hansen BC, Bodkin NL: Standardization of IVGTT. Importance of method used to calculate glucose disappearance. Diabetes Care 1993, 16:847.
• [19]Muniyappa R, Lee S, Chen H, Quon MJ: Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008, 294:E15-E26.
• [20]Lee S, Muniyappa R, Yan X, Chen H, Yue LQ, Hong EG, Kim JK, Quon MJ: Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice. Am J Physiol Endocrinol Metab 2008, 294:E261-E270.
• [21]Lee HW, Muniyappa R, Yan X, Yue LQ, Linden EH, Chen H, Hansen BC, Quon MJ: Comparison between surrogate indexes of insulin sensitivity/resistance and hyperinsulinemic euglycemic glucose clamps in rhesus monkeys. Endocrinology 2011, 152:414-423.
• [22]Polonsky KS, Rubenstein AH: C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 1984, 33:486-494.
• [23]Bonner-Weir S: Islet growth and development in the adult. J Mol Endocrinol 2000, 24:297-302.
• [24]Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
• [25]Gerich JE: Assessment of insulin resistance and its role in non-insulin-dependent diabetes mellitus. J Lab Clin Med 1984, 103:497-505.
• [26]Jones CN, Pei D, Staris P, Polonsky KS, Chen YD, Reaven GM: Alterations in the glucose-stimulated insulin secretory dose–response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab 1997, 82:1834-1838.
• [27]Wajchenberg BL: beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007, 28:187-218.
• [28]Bonora E: Protection of pancreatic beta-cells: is it feasible? Nutr Metab Cardiovasc Dis 2008, 18:74-83.
• [29]Cavaghan MK, Ehrmann DA, Polonsky KS: Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000, 106:329-333.
• [30]Radziuk J, Pye S, Seigler DE, Skyler JS, Offord R, Davies G: Splanchnic and systemic absorption of intraperitoneal insulin using a new double-tracer method. Am J Physiol 1994, 266:E750-E759.
• [31]Polonsky K, Jaspan J, Emmanouel D, Holmes K, Moossa AR: Differences in the hepatic and renal extraction of insulin and glucagon in the dog: evidence for saturability of insulin metabolism. Acta Endocrinol (Copenh) 1983, 102:420-427.
• [32]Sonksen PH, Tompkins CV, Srivastava MC, Nabarro JD: A comparative study on the metabolism of human insulin and porcine proinsulin in man. Clin Sci Mol Med 1973, 45:633-654.